Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Voyageur Secures First International Sales Contract worth US$1.9 Million (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Kamada Ltd KMDA

Healthcare Biotechnology
Kamada Ltd is Israel based company, focused on plasma-derived protein therapeutics with a commercial product portfolio and a late-stage product pipeline. The Company uses its proprietary platform technology and know-how for the extraction and purification of proteins from human plasma to produce Alpha-1 Antitrypsin (AAT) in a highly-purified, liquid form, as well as other plasma-derived Immune... see more

Recent & Breaking News (NDAQ:KMDA)

Kamada Reports 2013 Fourth Quarter and Full Year Financial Results

Business Wire February 5, 2014

Kamada to Host Fourth Quarter and Full Year 2013 Financial Results Conference Call on Wednesday, February 5, 2014

Business Wire January 30, 2014

Kamada Announces Completion of Pivotal Phase II/III Clinical Trial in Europe and Canada of Inhaled AAT to Treat Alpha-1 Antitrypsin Deficiency

Business Wire December 11, 2013

Kamada Announces Appointment of Amir London as Senior Vice President, Business Development

Business Wire December 9, 2013

Kamada Reports New Data from an Extension Study of its Phase I/II Trial with Glassia in Pediatric Patients with Type 1 Diabetes

Business Wire October 31, 2013

Kamada to Host Third Quarter 2013 Financial Results Conference Call on Tuesday, October 29, 2013

Business Wire October 21, 2013

Kamada to Present at September Investment Conferences

Business Wire September 4, 2013

Kamada Reports Second Quarter 2013 Financial Results

Business Wire August 1, 2013

Kamada to Host Second Quarter 2013 Financial Results Conference Call on Thursday, August 1, 2013

Business Wire July 25, 2013

Study Demonstrating Pancreatic Islet Xenograft Survival with Kamada's AAT Published in Peer-Reviewed Publication

Business Wire July 10, 2013

Kamada Announces Successful GMP Manufacturing Audit by Israel's Ministry of Health

Business Wire June 27, 2013

Kamada Granted Two Key Patents

Business Wire June 24, 2013

Kamada Announces Closing of Initial Public Offering and Over-Allotment Option Exercise

Business Wire June 5, 2013

NASDAQ Welcomes Kamada Ltd. [KMDA] to The NASDAQ Stock Market

Globe Newswire May 31, 2013